Robert Barrow

Robert Barrow

Chief Executive OfficeratDefinium Therapeutics· In proxies 2022–2025

Pay in FY2024+25% from the year before · Definium Therapeutics stock +90.2% the same year

Robert Barrow was paid $2.7M in FY2024 (Dec), up 25%. Definium Therapeutics stock rose 90.2% that year.

Pay$100 in the stock at the end of FY21 → $34
Pay is from the Summary Compensation Table of each Definium Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Definium TherapeuticsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role +55%
  2. Proxy StatementPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Definium TherapeuticsDirector · 4 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?